🔎 Trials Near Me

Home › Heart Failure › Tennessee

Heart Failure clinical trials in Tennessee

33 studies for Heart Failure are looking for participants at sites in Tennessee.

Cities in Tennessee

Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

  • Stern Cardiovascular Foundation, Inc., Germantown
  • Tennova Healthcare-Turkey Creek Medical Center, Knoxville
  • Vanderbilt University Medical Center, Nashville
  • and 1 more
RecruitingPhase 3
Ages 18 to 85 · All sexes · Updated Sep 24, 2026 · NCT06736574

Barostim-Enabled NEurohormonal Intervention For Improving Treatment of Heart Failure

  • Erlanger Health, Chattanooga
  • Stern Cardiovascular Center, Germantown
Recruiting
Ages 18 and older · All sexes · Updated Sep 23, 2026 · NCT07232030

A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure

  • Helios CR Inc, Jackson
  • East Coast Institute For Research LLC, Jefferson City
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06424288

Alleviant ALLAY-HFrEF Study

  • Tennova Healthcare - Turkey Creek Medical Center, Knoxville
Recruiting
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT06812533

Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

  • Apex Research Foundation, LLC, Jackson
  • The Jackson Clinic PA, Jackson
  • Parkway Cardiology Associates, Oak Ridge
  • and 2 more
RecruitingPhase 3
Ages 18 to 99 · All sexes · Updated Sep 16, 2026 · NCT07037459

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

  • Research Site, Cleveland
  • Research Site, Morristown
  • Research Site, Nashville
RecruitingPhase 3
Ages 40 and older · All sexes · Updated Sep 15, 2026 · NCT06677060

Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function

  • Research Site, Jackson
  • Research Site, Knoxville
  • Research Site, Memphis
  • and 2 more
RecruitingPhase 3
Ages 18 to 130 · All sexes · Updated Sep 11, 2026 · NCT06307652

A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients

  • Germantown, TN Investigative Site 10063, Germantown
  • Memphis, TN Investigative Site 10059, Memphis
  • Nashville, TN Investigative Site 10071, Nashville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06008197

A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients With Heart Failure (CONFIRMATION-HF)

  • CON-10051, Chattanooga, TN, Chattanooga
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 10, 2026 · NCT06024746

Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure

  • Baptist - Memphis (Stern), Memphis
Recruiting
Ages 18 to 100 · All sexes · Updated Sep 9, 2026 · NCT06310031

Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure

  • St.Thomas Health, Nashville
Recruiting
Ages 18 and older · All sexes · Updated Sep 4, 2026 · NCT07069738

Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036)

  • Le Bonheur Children's Hospital ( Site 0007), Memphis
RecruitingPhase 2/3
29 Days – 17 Years · All sexes · Updated Aug 28, 2026 · NCT05714085

Retinal Fundus Imaging and OCT Imaging for Ocular Detection of ATTR-CM

  • Research Site, Germantown
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 26, 2026 · NCT07690436

Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs

  • Vanderbilt University, Nashville
RecruitingObservational study
Up to age 18 · All sexes · Updated Aug 25, 2026 · NCT06532890

Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy

  • Vanderbilt University Medical Center, Nashville
RecruitingPhase 1
Ages 8 to 18 · Men · Updated Aug 24, 2026 · NCT07172971

Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

  • Germantown
  • Nashville
RecruitingObservational study
All ages · All sexes · Updated Aug 20, 2026 · NCT00271180

LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2

  • Tenax Investigational Site, Nashville
RecruitingPhase 3
Ages 18 to 85 · All sexes · Updated Aug 19, 2026 · NCT07288398

A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM)

  • Tristar Centennial Medical Ctr, Nashville
  • Saint Thomas Health, Nashville
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT05489705

A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

  • Balad Hlth Sys-Welmont CardCVA, Greeneville
  • The Jackson Clinic, PA, Jackson
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07567001

Alleviant ALLAY-HF Study

  • Stern Cardiovascular Foundation, Germantown
  • Tennova Healthcare - Turkey Creek Medical Center, Knoxville
Recruiting
Ages 40 and older · All sexes · Updated Aug 14, 2026 · NCT05685303

OPtimal Adult Heart Transplant Immunosuppression With MicroRNA Levels

  • Vanderbilt University, Nashville
RecruitingObservational study
Ages 18 to 99 · All sexes · Updated Aug 11, 2026 · NCT06939751

Assessment of CCM in HF With Higher Ejection Fraction

  • The Stern Cardiovascular Foundation, Germantown
Recruiting
Ages 18 and older · All sexes · Updated Aug 6, 2026 · NCT05064709

ELEVATE-HFpEF Clinical Study

  • Saint Thomas Research Institute, Nashville
Recruiting
Ages 40 and older · All sexes · Updated Aug 3, 2026 · NCT06678841

PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III

  • Vanderbilt, Nashville
Recruiting
Ages 18 and older · All sexes · Updated Jun 29, 2026 · NCT05934487

Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure

  • The Stern Cardiovascular Foundation, Memphis
Recruiting
Ages 18 and older · All sexes · Updated Jun 10, 2026 · NCT06526195

Wearable Technology to Evaluate Hyperglycemia and HRV in DMD

  • Vanderbilt University Medical Center, Nashville
RecruitingObservational studyHealthy volunteers welcome
Ages 10 and older · Men · Updated May 22, 2026 · NCT06124196

CCM OPEN HF Registry

  • The Stern Cardiovascular Foundation, Inc, Germantown
RecruitingObservational study
Ages 18 and older · All sexes · Updated Apr 23, 2026 · NCT07112924

The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR

  • Centennial Medical Center, Nashville
Recruiting
Ages 18 and older · All sexes · Updated Apr 13, 2026 · NCT03142152

XVIVO Heart Box (XHB) With Supplemented XVIVO Heart Solution (SXHS) Continued Access Protocol (CAP)

  • Vanderbilt University Medical Center, Nashville
Recruiting
Ages 18 and older · All sexes · Updated Mar 18, 2026 · NCT06895070

Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence

  • University of Tennessee Medical Center, Knoxville
  • University of Tennessee Health Science Center/Regional One Health, Memphis
Recruiting
Ages 18 and older · All sexes · Updated Jan 29, 2026 · NCT06374277

Wearable Technology to Evaluate Hyperglycemia and HRV in DMD - Longitudinal Aim

  • Vanderbilt University Medical Center, Nashville
RecruitingObservational study
Ages 10 and older · Men · Updated Nov 6, 2025 · NCT06093100

AN INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY TO ASSESS THE PERFORMANCE OF THE CORDIO HEARO SYSTEM

  • Vanderbilt University Medical Center, Nashville
RecruitingObservational study
Ages 22 and older · All sexes · Updated Mar 26, 2025 · NCT06378632

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.